Key Points:

• Iambic Therapeutics recorded the strongest return among the three companies shown, gaining 48.8% from its IPO.
• City Therapeutics delivered a 24.4% return following its October 15 offering, while Amaero gained 5.9% after its October 14 listing.
• Deal sizes varied considerably, from $20 million for Amaero to $200 million for City Therapeutics, highlighting the differences in scale across recent U.S. listings.

The U.S. initial public offering market continued to show varied results during the week of October 12–16, 2026. Data for three companies—City Therapeutics, Amaero and Iambic Therapeutics—showed positive returns from their respective IPOs, although the size of those gains differed significantly. The figures offer a snapshot of early aftermarket performance, while the relatively small sample does not establish a broader trend for the entire IPO market.

Therapeutics Listings Lead the Reported Returns

Iambic Therapeutics posted the strongest return among the three companies in the supplied data, rising 48.8% from its IPO price. Its current share price was listed at $23.81, with an offering date of October 14, 2026, and a deal size of $150 million. The return indicates substantial appreciation relative to its offering price, although the snapshot alone does not explain the drivers of that performance or establish whether the gains will persist.

City Therapeutics also recorded a positive return. With an October 15 offering date and a reported deal size of $200 million, the company had a listed current share price of $22.40 and a return from IPO of 24.4%. Its offering was the largest of the three transactions by deal size, making it a notable contributor to the week’s reported issuance activity.

Amaero Records a More Moderate Gain

Amaero reported a 5.9% return from IPO, the smallest gain among the three companies in the table. Its shares were listed at $4.50 following an October 14 offering, with a deal size of $20 million. Although its reported appreciation was more modest, the positive return shows that the three listings did not experience identical aftermarket outcomes.

The differences across the companies reinforce the importance of evaluating individual offerings rather than treating all new listings as a single market trend. Sector exposure, valuation, deal structure and investor expectations can influence aftermarket performance, but the supplied figures do not provide enough information to determine which factors drove these specific results.

What the Weekly Snapshot Signals for IPO Activity

The three offerings totaled $370 million in reported deal size. Iambic Therapeutics led in percentage return, while City Therapeutics had the largest deal. These figures illustrate how issuance scale and subsequent share-price performance can diverge.

Looking ahead, investors will need to monitor additional listings, trading activity and the durability of early returns to assess the broader condition of the U.S. IPO market. The postponement of Oura’s planned offering, described in the supplied background article, also underscores how market conditions can affect the timing of larger transactions. However, the three positive returns shown here are not sufficient to conclude that the wider IPO market has entered a sustained recovery.